Literature DB >> 10881749

Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex.

E L Saenko1, M Shima, A G Sarafanov.   

Abstract

Blood coagulation factor VIII (fVIII) in its nonactivated form circulates in plasma in a complex with von Willebrand factor (vWf). Upon activation by thrombin- or factor Xa-mediated site-specific proteolysis, activated fVIII (fVIIIa) serves as a cofactor for factor IXa. This protein complex assembled on a phospholipid surface (factor Xase) activates factor X. This complex plays the key role in the intrinsic pathway of blood coagulation. We reviewed the molecular events triggered by fVIII activation, which are required for the assembly and functioning of the Xase complex, including fVIIIa dissociation from vWf and a significant increase of fVIII affinity for binding to the phospholipid surface. Both events are mediated by activation-related cleavage within fVIII light chain (LCh), releasing the 40 amino-acid N-terminal LCh peptide, which is followed by a conformational change within the C2 domain. The conformational change within LCh is also required for the optimal fVIII cofactor functioning within the factor Xase complex, exerted via fVIIIa interactions with phospholipid, factor IXa, and factor X. Since factor IXa not only stabilizes but also proteolytically inactivates fVIIIa within the factor Xase complex, the stability of the membrane-bound fVIIIa in the presence and absence of factor IXa is discussed. In conclusion, we outline some new possible directions of the research. One of them arises from the recently demonstrated ability of plasma lipoproteins to provide a phospholipid surface for the assembly of the factor Xase complex in vitro. This finding raises a possibility that lipoproteins participate in factor Xase functioning in vivo and suggests a direct link between elevated levels of lipoproteins associated with atherosclerosis and increased thrombogenicity associated with this disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10881749     DOI: 10.1016/s1050-1738(00)00019-0

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  16 in total

1.  Reevaluation of the role of HDL in the anticoagulant activated protein C system in humans.

Authors:  Cecilia Oslakovic; Eva Norstrøm; Björn Dahlbäck
Journal:  J Clin Invest       Date:  2010-05       Impact factor: 14.808

2.  A mathematical model of coagulation under flow identifies factor V as a modifier of thrombin generation in hemophilia A.

Authors:  Kathryn G Link; Michael T Stobb; Matthew G Sorrells; Maria Bortot; Katherine Ruegg; Marilyn J Manco-Johnson; Jorge A Di Paola; Suzanne S Sindi; Aaron L Fogelson; Karin Leiderman; Keith B Neeves
Journal:  J Thromb Haemost       Date:  2019-11-01       Impact factor: 5.824

3.  Conservative mutations in the C2 domains of factor VIII and factor V alter phospholipid binding and cofactor activity.

Authors:  Gary E Gilbert; Valerie A Novakovic; Randal J Kaufman; Hongzhi Miao; Steven W Pipe
Journal:  Blood       Date:  2012-05-21       Impact factor: 22.113

Review 4.  Haemophilia A and haemophilia B: molecular insights.

Authors:  D J Bowen
Journal:  Mol Pathol       Date:  2002-04

5.  Synergy Between Tissue Factor and Exogenous Factor XIa in Initiating Coagulation.

Authors:  Karin Leiderman; William C Chang; Mikhail Ovanesov; Aaron L Fogelson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-10-27       Impact factor: 8.311

Review 6.  Haemophilia A and haemophilia B: molecular insights.

Authors:  D J Bowen
Journal:  Mol Pathol       Date:  2002-02

7.  Kinetics of Factor X activation by the membrane-bound complex of Factor IXa and Factor VIIIa.

Authors:  Mikhail A Panteleev; Evgueni L Saenko; Natalya M Ananyeva; Fazoil I Ataullakhanov
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

Review 8.  Factor VIII structure and function.

Authors:  Philip J Fay
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

9.  Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.

Authors:  Rolf Burghaus; Katrin Coboeken; Thomas Gaub; Lars Kuepfer; Anke Sensse; Hans-Ulrich Siegmund; Wolfgang Weiss; Wolfgang Mueck; Joerg Lippert
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

10.  Soluble phosphatidylserine binds to two sites on human factor IXa in a Ca2+ dependent fashion to specifically regulate structure and activity.

Authors:  Rinku Majumder; Tilen Koklic; Tanusree Sengupta; Daud Cole; Rima Chattopadhyay; Subir Biswas; Dougald Monroe; Barry R Lentz
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.